Abstract
The vast therapeutic benefits of plants have been recognized for centuries, yet there is still a large, untapped potential for commercial medicine production. In fact, several of the most important pharmaceuticals have been based on compounds found in natural products. Bioprospecting encompasses this search for the commercial potential of medicinal natural products. The search for these drugs from nature contains unique opportunities and challenges. Within the confines of the US pharmaceutical industry, the process of drug discovery must encompass the well-being of the countries and people from which the botanical information and specimen have been obtained, while conserving plant diversity and maintaining a competitive advantage in the industry. Nature contains incredibly unique chemical compounds of unparalleled diversity, ripe for new classes of therapeutics if care can be taken to ensure the benefit for local communities, the environment, and scientists. Therefore, this chapter describes triumphs and struggles of bioprospecting and framework for the future.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aratikatla EK, Valkute TR, Puri SK, Srivastava K, Bhattacharya AK (2017) Norepinephrine alkaloids as antiplasmodial agents: synthesis of syncarpamide and insight into the structure-activity relationships of its analogues as antiplasmodial agents. Eur J Med Chem 138:1089–1105. https://doi.org/10.1016/j.ejmech.2017.07.052
Atanasov AG et al (2015) Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol Adv 33:1582–1614. https://doi.org/10.1016/j.biotechadv.2015.08.001
Benz BF, Cevallos J, Santana F, Rosales J, Graf S (2000) Losing knowledge about plant use in the Sierra de Manantlan biosphere reserve, Mexico. Econ Bot 54:183–191
BMS (2011) TAXOL (paclitaxel) injection
Camp D, Davis RA, Campitelli M, Ebdon J, Quinn RJ (2012) Drug-like properties: guiding principles for the design of natural product libraries. J Nat Prod 75:72–81. https://doi.org/10.1021/np200687v
CBD (2011) Nagoya protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the convention on biological diversity. United Nations, Montreal
CBD (2017) Parties to the Nagoya protocol. Convention on Biological Diversity. https://www.cbd.int/abs/nagoya-protocol/signatories/default.shtml
CITES (n.d.) Convention on international trade in endangered species of wild fauna and flora appendices I, II, III
Danley V (2011) Biopiracy in the Brazilian Amazon: learning from International and comparative law successes and shortcomings to help promote biodiversity conservation in Brazil. Florida A & M Univ Law Rev 7:291
DeNicola GM et al (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475:106–109. https://doi.org/10.1038/nature10189
DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
Elvin-Lewis M (2007) Evolving concepts related to achieving benefit sharing for custodians of traditional knowledge. Afr J Tradit Complement Altern Med 4:443–468
Elvin-Lewis M (2011) Dereplications can amplify the extent and worth of traditional pharmacopeias. Afr J Tradit Complement Altern Med 8:13–26. https://doi.org/10.4314/ajtcam.v8i5S.12
ETC (2001) US Government’s $2.5 million biopiracy project in Mexico cancelled. ETC Group. http://www.etcgroup.org/fr/node/232
FDA (1999) Title, 21 C.F.R. S 314.108
Flamini G, Catalano S, Caponi C, Panizzi L, Morelli I (2002) Three anthrones from Rubus ulmifolius. Phytochemistry 59:873–876
Greaves T (1994) Intellectual property rights for indigenous peoples: a sourcebook. Society for Applied Anthropology, Oklahoma
Guenard D, Gueritte-Voegelein F, Potier P (1993) Taxol and taxotere: discovery, chemistry, and structure-activity relationships. Acc Chem Res 26:160–167. https://doi.org/10.1021/ar00028a005
Guerin-McManus M, Nnadozie KC, Laird SA (2002) The use of conservation trust funds for sharing financial benefits in bioprospecting projects. Adv Phytomed 1:211–240
Harvey AL (2008) Natural products in drug discovery. Drug Discov Today 13:894–901. https://doi.org/10.1016/j.drudis.2008.07.004
Hayden C (2003) When nature goes public: the making and unmaking of bioprospecting in Mexico. Princeton University Press, Princeton
Heinrich M (2001) Journal of Ethnopharmacology: an interdisciplinary journal devoted to indigenous drugs. J Ethnopharmacol 76:137–138. https://doi.org/10.1016/S0378-8741(01)00255-0
Hirshfeld AH (2014) 2014 Procedure for subject matter eligibility analysis of claims reciting or involving laws of nature/natural principles, natural phenomena, and/or natural products. Commissioner for Patents, Alexandria, VA
Holmes FA et al (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805. https://doi.org/10.1093/jnci/83.24.1797
Hunter P (2008) Harnessing nature’s wisdom. Turning to nature for inspiration and avoiding her follies. EMBO Rep 9:838–840. https://doi.org/10.1038/embor.2008.160
ISE (2006) International Society of Ethnobiology Code of Ethics (with 2008 additions). http://www.ethnobiology.net/what-we-do/core-programs/ise-ethics-program/code-of-ethics/code-in-english/
King S (1994) Establishing reciprocity: biodiversity, conservation and new models for cooperation between forest-dwelling peoples and the pharmaceutical industry intellectual property rights for indigenous peoples: a source book thomas greaves. Society for Applied Anthropology, Oklahoma
Krauss M (1992) The world’s languages in crisis. Language 68:4–10
Kursar TA (2011) What are the implications of the Nagoya protocol for research on biodiversity? Bioscience 61:256–257. https://doi.org/10.1525/bio.2011.61.4.2
Lee YK, Bang HJ, Oh JB, Whang WK (2017) Bioassay-guided isolated compounds from Morinda officinalis inhibit Alzheimer’s disease pathologies. Molecules 22. https://doi.org/10.3390/molecules22101638
Malik S, Cusidó RM, Mirjalili MH, Moyano E, Palazón J, Bonfill M (2011) Production of the anticancer drug taxol in Taxus baccata suspension cultures: a review Process. Biochemistry 46:23–34. https://doi.org/10.1016/j.procbio.2010.09.004
McGuire WP, Rowinsky EK, Rosenshein NB et al (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279. https://doi.org/10.7326/0003-4819-111-4-273
Medaglia JC, Silva CL (2007) Addressing the problems of access: protecting sources, while giving users certainty vol 1. IUCN, Gland
NCCIH (2015) Network pharmacology and natural products. https://nih.webex.com/nih/ldr.php?RCID=fdde5ac7b1aa12dbe78cda06f475f039
Ningthoujam SS, Talukdar AD, Potsangbam KS, Choudhury MD (2012) Challenges in developing medicinal plant databases for sharing ethnopharmacological knowledge. J Ethnopharmacol 141:9–32. https://doi.org/10.1016/j.jep.2012.02.042
Quezada F (2007) Status and potential of commercial bioprospecting activities in Latin America and the Caribbean. United Nations University Press, Tokyo
RAFI (1993) Bio-piracy: the story of natural coloured cottons of the Americas RAFI Communique
Ramirez CR (2007) Ethnobotany and the loss of traditional knowledge in the 21st century 2007 5:3 doi:https://doi.org/10.17348/era.5.0.245-247
RBGK (2017) The state of the World’s plants report 2017. Royal Botanic Gardens at Kew. https://stateoftheworldsplants.com/
Reyes-García V (2010) The relevance of traditional knowledge systems for ethnopharmacological research: theoretical and methodological contributions. J Ethnobiol Ethnomed 6:32. https://doi.org/10.1186/1746-4269-6-32
Reyes-García V et al (2013) Evidence of traditional knowledge loss among a contemporary indigenous society. Evol Hum Behav 34:249–257. https://doi.org/10.1016/j.evolhumbehav.2013.03.002
Richerzhagen C (2011) Effective governance of access and benefit-sharing under the convention on biological diversity. Biodivers Conserv 20:2243–2261
Robinson DF (2010) Confronting biopiracy: challenges, cases and international databases. Earthscan, London
Robles AJ et al (2017) Structure-activity relationships of new natural product-based diaryloxazoles with selective activity against androgen receptor-positive breast cancer cells. J Med Chem. https://doi.org/10.1021/acs.jmedchem.7b01228
Rocha DMAL (2003) Riqueza ameaçada
Rose J, Quave CL, Islam G (2012) The four-sided triangle of ethics in bioprospecting: pharmaceutical business, international politics, socio-environmental responsibility and the importance of local stakeholders. Ethnobiology and Conservation 1
Rosenthal JP (1997) Equitable sharing of biodiversity benefits: agreements on genetic resources. In: Investing in biological diversity: proceedings of the cairns conference, 1997. pp 253–274
Sampath PG (2005) Regulating bioprospecting: institutions for drug research, access and benefit-sharing. United Nations University Press, Tokyo
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665–667
Silva FÁ, Espindola LS (2011) Access legislation on genetic resources patrimony and traditional knowledge. Rev Bras 21
Stierle A, Strobel G, Stierle D (1993) Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science 260:214–216
Suffness M, Douros J (1982) Current status of the NCI plant and animal product program. J Nat Prod 45:1–14. https://doi.org/10.1021/np50019a001
UN (1992) Convention on biological diversity. Rio de Janeiro
USPAT (2015) General information concerning patents. United States Patent and Trademark Office
van Rozendaal ELM, Lelyveld GP, van Beek TA (2000) Screening of the needles of different yew species and cultivars for paclitaxel and related taxoids. Phytochemistry 53:383–389. https://doi.org/10.1016/S0031-9422(99)00094-1
Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325–2327. https://doi.org/10.1021/ja00738a045
WHO (2002) World health organization traditional medicine strategy 2002–2005. World Health Organization, Geneva
WHO (2003) World Health Organization guidelines on good agricultural and collection practices (GACP) for medicinal plants. World Health Organization, Geneva
WHO (2016) Overview of malaria treatment. World Health Organization, Geneva. http://www.who.int/malaria/areas/treatment/overview/en/
WHO (2017) WHO model list of essential medicine, 20th edn. World Health Organization, Geneva
Wong AY-T, Chen AW-K (2014) Myriad and its implications for patent protection of isolated natural products in the United States. Chin Med 9
Worthen DB (2004) American pharmaceutical patents from a historical perspective. Int J Pharmaceut Compound
WTO (1995) Trade-related aspects of intellectual property rights
Wynberg R, Schroeder D, Chennells R (2009) Indigenous peoples, consent and benefit sharing: lessons from the san-hoodia case. Springer, Berlin
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Cicka, D., Quave, C. (2019). Bioprospecting for Pharmaceuticals: An Overview and Vision for Future Access and Benefit Sharing. In: Joshee, N., Dhekney, S., Parajuli, P. (eds) Medicinal Plants. Springer, Cham. https://doi.org/10.1007/978-3-030-31269-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-31269-5_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31268-8
Online ISBN: 978-3-030-31269-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)